

Al Abbar Laboratories for Research and Medical Analysis مختبرات العبارللأبحاث و التحاليل الطبية



إدارة دبن للإعتماد طبقا لمواصفات الأيزو ١٥١٨٩ Dubai Accreditation Department for ISO 15189 المارة دبن للإعتماد طبقا لمواصفات الأيزو

LABORATORY REPORT

Name : ANTHONY KUNYURIA

File. No. : 22-07-1984 (39 Yrs 6 Month 27 Days/Male)

DOB/Gender

Referral Doctor : Dr. Sajid Sanaullah Khan

Lab No. : 22240490170 Referral Clinic : Peshawar(Irham Medical Center)

: AAL02-377468

Request Date : 18-02-2024 15:08

Clinic File No : 41939

Insurance : No

IMMUNOLOGY/SEROLOGY/INFECTIOUS DISEASES

Test Name Result Units Ref. Range Method

Non Reactive: <0.90 **Hepatitis B surface Ag** 0.42 **ECLIA** Cutoff Index (COI)

Borderline: >= 0.90 to < 1.0 Reactive: >= 1.0

Hepatitis B "s" Ag Interpretation Non-Reactive Non-Reactive

Full HepB profile is recommended in case of a Reactive result. HBs Ag Index value is an instrument dependant value and should not be used for monitoring.

For monitoring HepB levels (track treatment), a quantitative viral load by PCR is advised.

Samples should not be taken from patients receiving therapy with high biotin doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin administration.

Please note Reference Range Reviewed w.ef 20/10/23

Hepatitis C Virus Abs ECLIA Cutoff Index (COI) Non Reactive: <0.90

Borderline: >= 0.90 to < 1.0

Reactive: >=1.0

Non-Reactive Non-Reactive **Hepatitis C Virus Ab Interpretation**

Note: Patient with acute HCV infection may still be non-reactive for HCV abs ('diagnostic window'). Samples should not be taken from patients receiving therapy with high biotin doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin administration.

Please note Reference Range Reviewed w.ef 15/10/23

ECLIA Non Reactive: <1.0 HIV I & II Abs + p24 Ag 0.19Cutoff Index (COI)

Reactive: >=1.0

HIV Interpretation Non-Reactive Non-Reactive

Kindly note above test is just a screening test.

Note: Patients at a very early stage of infection may still be non-reactive for HIV Abs or detect p24 antigen. If HIV is suspected, a control sample is recommended in 4-6 weeks.

Samples should not be taken from patients receiving therapy with high biotin doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin administration.

Please note Reference Range Reviewed w.ef 15/10/23

Sample Type: Serum

----- End Of Report -----

These tests are accredited under ISO 15189:2012 unless specified by (*) Sample processed on the same day of receipt unless specified otherwise. Test results pertains only the sample tested and to be correlated with clinical history.

Reference range related to Age/Gender.

Dr. Solmaz Siddiqui

Authenticated On: 18-02-2024 17:14:12 Printed On: 18-02-2024 19:42:12

H/L Collected On: 18-02-2024 14:00:00

Received On: 18-02-2024 15:08:00

Released On: 18-02-2024 17:19:23

Rhea Suberon

Medical Laboratory Technician

DHA/LS/123639

Laboratory Director DHA/LS/248469

